PLUR peer analysis
Pluri (PLUR) against its competitors: price, today's move, 1-year return and market value side by side.
- PLUR's peers: ANTX (AN2 Therapeutics), BOLD (Boundless Bio), IBIO (iBio), INTS (Intensity Therapeutics), JSPR (Jasper Therapeutics), NXTC (NextCure), QTTB (Q32 Bio), SABS (SAB Biotherapeutics).
PLUR and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ANTX AN2 Therapeutics | $5.22 | 5.45% | 383.33% | $198.07M |
| BOLD Boundless Bio | $2.38 | -0.83% | 106.96% | $56.20M |
| IBIO iBio | $0.80 | -5.55% | -26.51% | $56.44M |
| INTS Intensity Therapeutics | $2.50 | -5.30% | -76.60% | $8.25M |
| JSPR Jasper Therapeutics | $10.75 | -6.68% | -80.63% | $11.92M |
| NXTC NextCure | $6.78 | -1.53% | -27.56% | $31.05M |
| QTTB Q32 Bio | $8.18 | -3.54% | 285.85% | $244.78M |
| SABS SAB Biotherapeutics | $2.82 | -3.09% | -26.37% | $254.05M |
| PLUR Pluri | $0.97 | 5.98% | -73.43% | $13.94M |